Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian Direct-To-OTC Sale Of Nicotine Inhaler Proposed

This article was originally published in The Tan Sheet

Executive Summary

The Canadian Therapeutic Products Programme is soliciting comments on nonprescription availability of nicotine inhalation devices.

You may also be interested in...



J&J/Merck Pepcid Complete Combines H2 Antagonist/Antacid Ingredients

J&J/Merck's Pepcid Complete is the first OTC stomach remedy to combine a fast-acting antacid ingredient with a long-term acid control ingredient, according to the firm. FDA approved NDA 20-958 for Pepcid Complete Oct. 16.

Nicotine Replacement Combination Therapy Urged In PHS Clinical Guidelines

Patients unable to quit smoking using a single type of first-line pharmacotherapy should be encouraged to use a combined treatment consisting of a nicotine patch and another form of nicotine replacement therapy (NRT) such as a gum or nasal spray, according to new clinical practice guidelines released June 27.

McNeil Nicotrol Inhaler Rx test marketing.

McNEIL NICOTROL INHALER Rx TEST MARKETING commenced in February in Houston, Tex. and will begin in March in Baltimore, Md. The hand-held inhaler delivers menthol-flavored nicotine to its user with each draw, mimicking the act of smoking. McNeil Consumer Products expects to launch the prescription smoking cessation product nationwide during the third or fourth quarter. The long test market may be due to the learning curve for inhaler use by consumers.

Related Content

Topics

UsernamePublicRestriction

Register

PS091923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel